Sanofi builds case for Toujeo in younger type 1 diabeticsSanofi’s Toujeo – a follow-up to its long-acting insulin drug Lantus – has underperformed commercially since launch but Share XSanofi builds case for Toujeo in younger type 1 diabeticshttps://pharmaphorum.com/news/sanofi-builds-case-for-toujeo-in-younger-type-1-diabetics/
Real-world diabetes study CONFIRMs positive comparative efficacy for Novo’s TresibaNovo Nordisk presented the latest results for its diabetes injectable Tresiba last weekend. These demonstrated significantly better control Share XReal-world diabetes study CONFIRMs positive comparative efficacy for Novo’s Tresibahttps://pharmaphorum.com/news/tresiba-improved-sugar-control-decreased-hypos/
